TOGETHER 2010.

Methods	Individual-level randomised, double dummy controlled trial
Participants	244 participants (122 intervention; 122 control) with history of hypertension but no history of CVD or diabetes with ≥2 risk factors: age ≥45 years for men; ≥55 years for women; current smoker; family history of premature coronary heart disease in first degree relative; HDL cholesterol <40 mg/dl; waist circumference >102 cm in men and >88 cm in women
Interventions	Intervention: single pill amlodipine (5/10mg) plus atorvastatin 20mg + therapeutic lifestyle changes Control: amlodipine (5/10mg) + therapeutic lifestyle changes
Outcomes	Proportion achieving a BP goal <140/90 mmHg and LDL-C<100 mg/dl at week 6; BP and LDL-C goal at week 4; BP goal at weeks 4 and 6; change in SBP, DBP, LDL-C, total cholesterol, HDL-C, triglycerides at weeks 4 and 6; predicted 10 year Framingham coronary heart disease risk score, adverse events
Notes	Control: active
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Central, computer based telerandomisation
Allocation concealment (selection bias)	Low risk	Central, computer based telerandomisation
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind labeled bottles but unclear if pills were identical
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Reportedly double blinded
Incomplete outcome data (attrition bias) All outcomes	High risk	Last observation carried forward used for non-completers for final analysis
Selective reporting (reporting bias)	Unclear risk	Primary outcomes reported